This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| glucagon-like peptide-1 | |
|---|---|
| Name | Glucagon-like peptide-1 |
| Organism | Humans |
| Length | 30–37 amino acids (active forms) |
glucagon-like peptide-1 is an incretin hormone derived from the proglucagon precursor produced primarily in intestinal L cells and some neurons. It acts through a G protein–coupled receptor to regulate insulin secretion, appetite, gastric emptying, and cardiovascular function, with major implications for metabolic diseases and therapeutics.
The peptide is generated from the prohormone convertase 1/3 processing of the proglucagon gene product in enteroendocrine L cells of the ileum and colon, and by prohormone convertase 2 in pancreatic α cells, yielding multiple peptides including GLP-1(7–37) and GLP-1(7–36)amide. Biosynthetic regulation involves transcriptional control by factors such as FOXO1, Pdx1, and NeuroD1 in gut and neural tissues, and post-translational modification by dipeptidyl peptidase-4 and neutral endopeptidase produces truncated, inactive forms. Structural studies using X-ray crystallography and nuclear magnetic resonance mapping of GLP-1 fragments informed design of receptor agonists exploited by pharmaceutical companies like Eli Lilly and Company and Novo Nordisk.
GLP-1 mediates enteroinsular signaling linking nutrient ingestion to pancreatic hormone responses studied in cohorts investigated by Framingham Heart Study-style epidemiology. It enhances glucose-dependent insulin secretion evaluated in clinical trials run by institutions such as Mayo Clinic, Harvard Medical School, and Imperial College London. Central nervous system actions on appetite and satiety are mapped to nuclei studied at institutions including Karolinska Institutet, University of Cambridge, and Massachusetts Institute of Technology. Peripheral effects include slowed gastric emptying characterized in gastric physiology studies associated with Mayo Clinic Arizona and cardioprotective phenomena examined by investigators at Cleveland Clinic and Johns Hopkins University.
The GLP-1 receptor is a class B G protein–coupled receptor first cloned in laboratories at institutions like University College London and University of California, San Diego. Receptor activation triggers adenylate cyclase and cAMP production, engaging effectors such as protein kinase A and exchange protein directly activated by cAMP pathways elucidated in cell biology studies at Max Planck Society and Cold Spring Harbor Laboratory. Biased agonism, receptor internalization, and β-arrestin recruitment have been characterized using techniques refined at Salk Institute and Broad Institute. Heterodimerization with other GPCRs has been probed by research groups at Stanford University and University of Oxford.
GLP-1 amplifies glucose-stimulated insulin secretion from pancreatic β cells, a mechanism central to therapies evaluated by American Diabetes Association guidelines and trials sponsored by National Institutes of Health. It inhibits glucagon release from pancreatic α cells, an effect relevant to studies at European Association for the Study of Diabetes and trials reported in journals from British Medical Journal and The Lancet. Deficient incretin response in type 2 diabetes was documented in longitudinal cohorts such as UK Biobank and interventions compared across multicenter trials involving Karolinska University Hospital and Mayo Clinic. Preservation of β-cell mass via antiapoptotic signaling has been investigated by teams at University of Pennsylvania and Northwestern University.
GLP-1 receptor agonists are employed for glycemic control and weight management in guidelines promulgated by World Health Organization and American Association of Clinical Endocrinologists. Semaglutide, liraglutide, exenatide, dulaglutide, and albiglutide were developed by companies including Novo Nordisk, Eli Lilly and Company, and AstraZeneca, and tested in outcome trials such as those run by REWIND investigators and cardiovascular outcome trials conducted by consortia involving European Medicines Agency oversight. Combination therapies pairing GLP-1 agonists with agents from Sanofi or coformulations with basal insulin were evaluated in randomized controlled trials at centers including Cleveland Clinic and Karolinska Institutet.
Common adverse effects—nausea, vomiting, and diarrhea—were reported in postmarketing surveillance systems managed by agencies such as Food and Drug Administration and European Medicines Agency. Rare but serious concerns including pancreatitis and potential thyroid C‑cell hyperplasia prompted regulatory review by bodies like Committee for Medicinal Products for Human Use and safety committees convened at World Health Organization. Cardiovascular safety has been assessed in large outcome trials led by networks including Duke University and Columbia University Irving Medical Center, while long-term safety studies are ongoing in cohorts tracked by UK Biobank and national registries such as Swedish National Diabetes Register.
Ongoing research explores dual and triple agonists combining GLP-1 activity with GIP and glucagon receptor targeting, developed in partnerships between Harvard Medical School spinouts and biotech firms like Moderna-adjacent ventures and small companies incubated at Cambridge Science Park. Neurodegenerative disease applications are investigated in preclinical programs at Massachusetts General Hospital and translational centers at Toronto General Hospital. Obesity treatment paradigms informed by trials at NIH and policy assessments by World Obesity Federation drive large pragmatic studies in health systems such as Kaiser Permanente. Novel delivery systems including oral formulations and long‑acting implants are advanced by collaborations with engineering groups at MIT and ETH Zurich.
Category:Peptide hormones